B
ZNTL icon

Bailard’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Bailard’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-26,000
Closed -$1.73M – 793
2021
Q3 		$1.73M Sell
26,000
-5,500
-17% -$317K 0.06% 212
2021
Q2 		$1.68M Buy
+31,500
New +$1.69M 0.06% 217

Other funds holding ZNTL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Bailard's ZNTL Position: Q4 2021 in Review

Bailard sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2021, closing a stake of 26,000 shares — an estimated $1.73M sold.

Bailard first reported a position in ZNTL in Q2 2021 and held it in 2 quarters. The position peaked at $1.73M in Q3 2021. 139 funds tracked by Wall St. Rank hold ZNTL as of Q4 2021.

  • Bailard reported no remaining Zentalis Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Bailard sold 26,000 Zentalis Pharmaceuticals shares in Q4 2021, an estimated $1.73M.
  • Bailard first reported a position in Zentalis Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • Bailard's Zentalis Pharmaceuticals position peaked at $1.73M in Q3 2021.
  • 139 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2021.

Based on Bailard's 13F filing for Q4 2021, filed 10 Feb 2022.